Literature DB >> 1475176

High pressure liquid chromatographic analysis of the serum concentration of cefuroxime after an intravenous bolus injection of cefuroxime in patients with a coronary artery bypass grafting.

M J Koot1, F N IJdenberg, R M Stuurman, J Poell, L J Bras, J J Langemeijer, L Lie-A-Huen.   

Abstract

A simple reversed-phase high pressure liquid chromatographic method was developed for the determination of cefuroxime in the serum of patients undergoing coronary artery bypass grafting. The serum was cleaned up with a 3.3% solution of perchloric acid in water. Cefalexine was used as an internal standard. Detection was made by a UV multi-wavelength detector. The optimum wavelength for cefuroxime is 275 nm. The absolute recovery of this method was 90.9%; the limit of quantification was 0.7 mg/l. This analytical method was used in a study to investigate the cefuroxime serum concentration--time curves in 26 patients undergoing coronary artery bypass grafting. It was found that one single dose is sufficient to obtain effective serum concentrations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1475176     DOI: 10.1007/bf01970173

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  8 in total

1.  Cefuroxime concentrations in serum, urine and bile: pharmacokinetic profile.

Authors:  J M Brogard; J Kopferschmitt; M Pinget; J P Arnaud; J Lavillaureix
Journal:  Proc R Soc Med       Date:  1977

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  Recent analytical methods for cephalosporins in biological fluids.

Authors:  R D Toothaker; D S Wright; L A Pachla
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

4.  Determination of cefsulodin, cefotiam, cephalexin, cefotaxime, desacetyl-cefotaxime, cefuroxime and cefroxadin in plasma and urine by high-performance liquid chromatography.

Authors:  J B Lecaillon; M C Rouan; C Souppart; N Febvre; F Juge
Journal:  J Chromatogr       Date:  1982-03-12

5.  Determination of cephalosporins in biological material by reversed-phase liquid column chromatography.

Authors:  A M Brisson; J B Fourtillan
Journal:  J Chromatogr       Date:  1981-05-08

6.  Pharmacokinetics of cefuroxime in normal and impaired renal function: comparison of high-pressure liquid chromatography and microbiological assays.

Authors:  R W Bundtzen; R D Toothaker; O S Nielson; P O Madsen; P G Welling; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

Review 7.  Cefuroxime: mechanisms of action, antimicrobial activity, pharmacokinetics, clinical applications, adverse reactions and therapeutic indications.

Authors:  B Gold; W J Rodriguez
Journal:  Pharmacotherapy       Date:  1983 Mar-Apr       Impact factor: 4.705

Review 8.  Review of the new second-generation cephalosporins: cefonicid, ceforanide, and cefuroxime.

Authors:  T A Tartaglione; R E Polk
Journal:  Drug Intell Clin Pharm       Date:  1985-03
  8 in total
  4 in total

1.  A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function.

Authors:  Anders Viberg; Anders Lannergård; Anders Larsson; Otto Cars; Mats O Karlsson; Marie Sandström
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

2.  Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting.

Authors:  S M Nooyen; B P Overbeek; A Brutel de la Rivière; A J Storm; J J Langemeyer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-12       Impact factor: 3.267

3.  Targeting cefuroxime plasma concentrations during coronary artery bypass graft surgery with cardiopulmonary bypass.

Authors:  Marieke Aalbers; Peter G J ter Horst; Wobbe Hospes; Michel L Hijmering; Alexander J Spanjersberg
Journal:  Int J Clin Pharm       Date:  2015-03-20

4.  Clinical on-site monitoring of ß-lactam antibiotics for a personalized antibiotherapy.

Authors:  R Bruch; C Chatelle; A Kling; B Rebmann; S Wirth; S Schumann; W Weber; C Dincer; G Urban
Journal:  Sci Rep       Date:  2017-06-09       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.